Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 18, 1998

View Archived Issues

MK-966 improves physical ability and quality of life in patients with OA, RA

New Maxamine data to be presented at annual symposium

Study completed on new therapy for traveler's diarrhea

Study shows Zadaxin plus chemotherapy inhibits cancerous tumors in mice

Myriad Genetics and Monsanto collaborate on drug target discovery

Amgen: Q3 1998 highlights

Cytel receives FDA grant to further development of selectin inhibitor

Axis Genetics enters collaboration for edible plant vaccine development

Vical provides clinical update of Allovectin-7 in treatment of head and neck cancer

Triangle Pharmaceuticals presents preliminary data on FTC in HBV patients

Novel MMP inhibitor synthesized at Abbott shows potent antitumor activity in vivo

New osteoarthritis treatment candidate blocks cartilage degradation

SB pursues CCR5 antagonists for the treatment of inflammation

MMP inhibitor BMS-453 improves disease symptoms in mice with experimental arthritis

Synthesis and use of novel ET-antagonist series disclosed by Merck KGaA

5-HT antagonists in development at Synthelabo for cardiovascular and other disorders

Novel antibody with potential in treating RA investigated by Santen

Synthelabo discloses orally active human thrombin inhibitors

Vanadocene complexes exert potent spermicidal effects in vitro; further study recommended

Potent and selective 5-HT1A/5-HT1B/5-HT1D receptor antagonists discovered at Pierre Fabre

New thiazolidinediones for diabetes reported in patent literature by Boehringer Mannheim

Abbott reports in vitro and in vivo antimycobacterial activity of new 2-pyridone

Lamivudine highlighted at recent Study for Liver Diseases meeting

Dutasteride outshines finasteride in BPH Rx

Animal data suggest that GPI-1046 may be useful in glaucoma

New flu pill helps patients quickly return to normal, improving health, sleep and activity

NIAID reports important reduction in latently infected cell pool in patients on HAART + IL-2

FDA advisory committee issues positive statement on DepoCyt

Igmesine: mode of action and preclinical antidepressant activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...